Adamax commonly refers to an N-acetylated Semax variant sold in research catalogs. Acetylation alters N-terminal charge and may affect stability and permeability in model systems — it is a distinct chemical entity from unmodified Semax.
CGRP is a sensory neuropeptide central to migraine pathophysiology research and the target of multiple approved therapeutics. Native α-CGRP and β-CGRP isoforms differ by three residues — catalog material must specify which sequence is supplied.
Dihexa is a synthetic oligopeptide developed as a small-molecule mimetic of hepatocyte growth factor signaling. Preclinical literature emphasizes synaptogenesis and cognitive endpoints in rodent models — with no established human clinical program for catalog material.
DSIP is a nine-residue peptide originally isolated from rabbit brain and associated with sleep-induction research dating to the 1970s. Human and animal studies report mixed, often modest effects on sleep and stress biomarkers — with replication gaps across decades.
Melanotan II is a synthetic cyclic heptapeptide melanocortin agonist studied in melanogenesis, pigmentation, and central melanocortin signaling research. It is chemically related to bremelanotide (PT-141) but is not an FDA-approved drug product.
N-acetyl Selank amidate applies N-terminal acetylation and C-terminal amidation to the Selank heptapeptide sequence. Catalog listings treat it as a stabilized Selank derivative, but peer-reviewed literature on this exact modified sequence is thinner than for parent Selank.
N-acetyl Semax amidate combines N-terminal acetylation with C-terminal amidation on the Semax heptapeptide backbone. Both modifications are common medicinal-chemistry strategies for peptide stability — the result is a chemically distinct research material from Semax and Adamax.
Oxytocin is among the best-studied neuropeptides in neuroscience and endocrinology, with approved pharmaceutical formulations for defined obstetric indications and a vast experimental literature on social cognition — categories that should not be conflated with catalog RUO material.
P21 is a synthetic peptide derived from ciliary neurotrophic factor (CNTF) sequence logic, studied in preclinical models of neurogenesis and cognitive recovery after brain injury. Catalog naming overlaps with unrelated cell-cycle terminology — sequence confirmation is essential.
PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist derived from melanocortin peptide chemistry. It has published phase 3 clinical literature for central sexual-arousal pathways and is FDA-approved as Vyleesi — distinct from catalog RUO material without pharmaceutical documentation.
Selank is a synthetic heptapeptide derived from tuftsin with an added Gly-Pro C-terminal extension. Russian and Western literature describes anxiolytic-like effects in rodent models without classical benzodiazepine sedation, plus immunomodulatory research angles.
Semax is a synthetic heptapeptide analog of the ACTH(4-10) fragment developed in Russian neuropharmacology programs. Western-indexed literature explores neurotrophic gene expression, BDNF-related signaling, and neuroprotection in rodent models.
VIP is a widely distributed neuropeptide with extensive formal research in immunology, circadian biology, and neuroprotection. It is analytically well characterized but sensitive to oxidation and proteolysis — material handling matters as much as sequence identity.
Ziconotide is a marine-derived conopeptide approved as an intrathecal analgesic for severe chronic pain — a rare example of a catalog-discussed peptide with full regulatory approval under defined administration constraints. RUO supply is not the approved drug product.
Community content — not medical advice. Research use only; nothing here is instruction for human use.
We use strictly necessary cookies to run the site (your sign-in session and this choice). With your consent we also use analytics cookies to improve the site. See our Cookie Policy and Privacy Policy.